so

I think...

Well, the question crosses a couple of dimensions.

Scientifically, I think there's a lot of incredible work that's going on.

Australia is globally on the forefront of legalizing MDMA and psilocybin for psychedelic assisted therapy.

I'm not up to date on all the current research, but there's research continuing around the world.

I think for Ibogaine, the research, there's still only really early human trials that have, I mean, that's relative, that have low sample sizes, but they've shown to be really positive.

And so how do you approach medical screening, monitoring? How do you decide with this medicine who is a suitable candidate and potentially who's not a suitable candidate?